Company intelligence / Profile preview

Avenacy

Schaumburg, Illinois, United Statesavenacy.com ↗

Ownership: Private
Development stage: Commercial

Overview

Avenacy has rapidly launched a portfolio of over twenty FDA-approved sterile injectable medications since its founding in late 2023. The company focuses on high-quality generics that address supply shortages in U.S. hospitals and clinics. Its differentiated packaging aims to improve patient safety by reducing administration errors. Recent launches include multiple antibiotic injectables such as doxycycline for injection. Clinical results are not applicable as these are generic drugs.

Therapeutic areas: OtherInfectious Diseases
Modalities: Sterile injectables (primarily small molecules/generics)
Industry: Biotech

Drug pipeline

1 asset

tranexamic acid

Commercial

Indications: Hemophilia

Partnerships

Global network of development and contract manufacturing partners who have passed FDA cGMP inspections.

Beyond the preview

Go deeper on Avenacy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avenacy.

Explore the full profile